Workflow
NovelBeam Technology(688677)
icon
Search documents
海泰新光:2024年三季报点评:24Q3短期承压,预计Q4发货有所改善
Southwest Securities· 2024-11-05 11:17
Investment Rating - Buy (Maintained) with a target price of 50.40 yuan (6 months) [1] Core Views - The company's Q3 2024 performance was under short-term pressure, but Q4 shipments are expected to improve [1] - The core product, artificial heart valves, continues to drive growth, with a 42.8% YoY increase in revenue [1] - The company is deepening its cooperation with Stryker, benefiting from the global trend of fluorescence replacing white light in endoscopy [3] - Domestic strategy focuses on multi-category endoscope development and brand building in key medical fields [3] Financial Performance - Q3 2024 revenue was 0.98 billion yuan, down 9.4% YoY, with net profit of 0.27 billion yuan, down 7.0% YoY [3] - Q1-Q3 2024 revenue was 3.2 billion yuan, down 15.3% YoY, with net profit of 0.97 billion yuan, down 17.6% YoY [3] - Gross margin for Q1-Q3 2024 was 89.7%, up 1.5 percentage points YoY, driven by higher-margin products [1] R&D and Product Pipeline - R&D expenses for Q1-Q3 2024 were 446 million yuan, accounting for 20.2% of revenue [2] - Key products in development include the Renato® and Renatus® heart valve systems, with clinical trials progressing as planned [2] - The company is advancing its pipeline in surgical soft tissue repair, including ophthalmic and vascular biological patches [2] Market and Industry Trends - The global trend of fluorescence replacing white light in endoscopy is creating significant industry opportunities [3] - The company's second-generation 4K endoscope system has shipped over 100 units since its launch in early 2024 [3] - The industry is moving towards multi-technology integration, including fluorescence, 4K, and 3D [3] Profit Forecast and Valuation - Forecasted net profit for 2024-2026 is 1.4, 2, and 2.5 billion yuan, respectively [3] - The company is valued at 30x PE for 2025, with a target price of 50.4 yuan [3] Business Segments - Medical devices segment is expected to grow 20%, 32%, and 14% YoY in 2024-2026, with stable pricing [6] - Optical devices segment is expected to decline 16% in 2024 but grow 9.5% in 2025 and 2026 [6] - Endoscope maintenance segment is expected to grow 15% annually from 2024 to 2026 [7]
海泰新光:2024年三季报点评:Q3收入降幅收窄,整机持续放量
Huachuang Securities· 2024-11-05 10:33
Investment Rating - The report maintains a "Recommend" rating for Haite High-Tech (688677) with a target price of 43 RMB, compared to the current price of 37.02 RMB [1] Core Views - Revenue decline narrowed in Q3, with continued growth in whole-machine sales [1] - Customer inventory reduction temporarily pressured performance, but shipments are expected to gradually recover as customer inventory reaches lower levels [1] - Increased expenses in the first three quarters led to a larger decline in net profit attributable to parent company compared to revenue decline [1] - Product structure changes improved profitability, with higher gross margin products increasing their shipment proportion [1] - Whole-machine business performed exceptionally well, with second-generation 4K endoscope system sales exceeding 100 units in the domestic market in H1, achieving 200% YoY revenue growth [1] Financial Performance - Q3 revenue: 98 million RMB (-9.39% YoY) [1] - Q3 net profit attributable to parent company: 27 million RMB (-7.00% YoY) [1] - Q1-Q3 revenue: 319 million RMB (-15.30% YoY) [1] - Q1-Q3 net profit attributable to parent company: 97 million RMB (-17.60% YoY) [1] - Q3 gross margin improved to 69.44% (+5.38pct YoY) [1] Future Projections - 2024-2026 revenue forecast: 431 million RMB (-8.4% YoY), 549 million RMB (+27.5% YoY), 685 million RMB (+24.7% YoY) [3] - 2024-2026 net profit attributable to parent company forecast: 137 million RMB (-5.9% YoY), 186 million RMB (+35.7% YoY), 234 million RMB (+25.7% YoY) [3] - 2024-2026 EPS forecast: 1.14 RMB, 1.54 RMB, 1.94 RMB [3] Business Development - The company is actively expanding its domestic market and improving its marketing network [1] - Ongoing R&D investment and acceleration of overseas factory construction [1] - Second-generation 4K endoscope system achieved significant sales growth in the domestic market [1]
海泰新光:2024三季报点评:降库存影响收窄,订单量持续恢复
Guoyuan Securities· 2024-11-05 09:39
Investment Rating - The report maintains a "Buy" rating for the company [5][7] Core Views - The company's revenue and net profit declined in the first three quarters of 2024 due to inventory reduction by its core customer Stryker However the impact is gradually weakening and order volumes are expected to recover [2][3] - The company's third-quarter performance showed a narrowing decline with Q3 revenue of 98 million yuan down 9 39% YoY and net profit of 27 million yuan down 7 00% YoY [3] - The company's overseas factory construction is progressing smoothly with the Thailand factory expected to apply for capacity expansion by the end of the year Domestic promotion of self-branded equipment is also poised for full commercialization in 2025 [4] - The company's gross margin remained stable at 65 74% in Q1-3 2024 while net margin slightly decreased to 30 26% [3] Financial Performance - For Q1-3 2024 the company achieved revenue of 319 million yuan down 15 30% YoY and net profit of 97 million yuan down 17 60% YoY [2] - The company's EPS for Q1-3 2024 was 0 81 yuan [2] - The company's operating efficiency remained stable with a gross margin of 65 74% (+1 64pct) and a net margin of 30 26% (-0 52pct) in Q1-3 2024 [3] - The company's sales expense ratio increased to 4 91% (+1 43pct) while R&D expense ratio rose to 14 80% (+0 39pct) [3] Future Projections - The company is expected to achieve revenue of 442 million yuan 545 million yuan and 676 million yuan in 2024 2025 and 2026 respectively [5] - Net profit is projected to be 138 million yuan 195 million yuan and 245 million yuan for 2024 2025 and 2026 respectively [5] - EPS is forecasted to be 1 14 yuan/share 1 64 yuan/share and 2 08 yuan/share for 2024 2025 and 2026 respectively [5] - The company's PE ratio is expected to be 34x 23x and 18x for 2024 2025 and 2026 respectively [5] Operational Highlights - The company has completed the construction of a light source module production line at its Thailand factory which will help reduce tariff impacts [4] - The domestic distribution system for self-branded equipment has been established with full commercialization expected to begin in 2025 [4] - The company's self-branded equipment sales are expected to significantly improve profitability due to higher gross margins [4]
海泰新光:海泰新光关于股份回购实施结果暨股份变动的公告
2024-11-04 11:32
证券代码:688677 证券简称:海泰新光 公告编号:2024-066 青岛海泰新光科技股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: | 回购方案首次披露日 | 2024/5/9 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 万元~5,000 万元 2,600 | | 回购价格上限 | 69 元/股 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 实际回购股数 | 万股 73.7 | | 实际回购股数占总股本比例 | 0.6110% | | 实际回购金额 | 万元 2,610.96 | | 实际回购价格区间 | 28.89 元/股~40.75 元/股 | 一、 回购审批情况和回购方案内容 2024 年 5 月 8 日,公司召开第三届董事会第二十次会议,审议通过了《关于 以集中竞价交易方式回 ...
海泰新光:业绩短期承压,大客户去库尾声,拐点将至
Xinda Securities· 2024-11-03 02:00
Investment Rating - The report maintains a positive outlook on the company, indicating a potential recovery in revenue growth as the inventory reduction by major US customers nears its end [1] Core Views - The company's revenue for the first three quarters of 2024 was RMB 319 million (yoy -15 30%), with net profit attributable to the parent company at RMB 97 40 million (yoy -17 60%) [1] - Revenue in Q3 2024 was RMB 98 25 million (yoy -9 39%), showing a narrowing decline compared to previous quarters, suggesting the inventory reduction cycle is nearing its end [1] - The company's gross profit margin in Q3 2024 improved to 69 44% (yoy +5pp), driven by higher-margin products [1] - The company's second growth driver, the whole machine business, continued to grow significantly in Q3 2024, providing new momentum for future growth [1] Financial Performance Summary - Revenue for 2024E is projected at RMB 436 million (yoy -7 4%), with a recovery expected in 2025E and 2026E to RMB 555 million (yoy +27 3%) and RMB 684 million (yoy +23 3%) respectively [2] - Net profit attributable to the parent company is forecasted to grow from RMB 155 million in 2024E to RMB 254 million in 2026E, with a CAGR of 25 7% [2] - Gross profit margin is expected to remain stable at around 63 9% from 2024E to 2026E [2] - ROE is projected to improve from 11 7% in 2024E to 15 8% in 2026E, reflecting better profitability and efficiency [2] Business Outlook - The company's revenue growth is expected to recover as the inventory reduction by major US customers concludes, with shipments expected to gradually increase [1] - The whole machine business is anticipated to become a significant growth driver, contributing to the company's future revenue expansion [1] - The company's profitability is expected to remain stable, with potential for improvement as revenue scales up and expenses are diluted [1] Valuation Metrics - The company's P/E ratio is projected to decline from 29 84x in 2024E to 18 23x in 2026E, reflecting expected earnings growth [2] - The P/B ratio is forecasted to decrease from 3 48x in 2024E to 2 88x in 2026E, indicating potential undervaluation as the company's book value grows [2]
海泰新光:青岛海泰新光科技股份有限公司2024年第四次临时股东大会会议资料
2024-11-01 13:46
青岛海泰新光科技股份有限公司 2024 年第四次临时股东大会会议资料 2024 年 11 月 青岛海泰新光科技股份有限公司 2024 年第四次临时股东大会会议资料 目录 | 青岛海泰新光科技股份有限公司 2024 年第四次临时股东大会会议须知 1 | | --- | | 青岛海泰新光科技股份有限公司 2024 年第四次临时股东大会会议议程 3 | | 议案一、《关于投保董事、监事及高级管理人员等人员责任保险的议案》 ... 4 | | 议案二:《关于修订<青岛海泰新光科技股份有限公司对外投资管理制度>的议 | | 案》 5 | 青岛海泰新光科技股份有限公司 2024 年第四次临时股东大会会议资料 青岛海泰新光科技股份有限公司 2024 年第四次临时股东大会会议资料 证券代码:688677 证券简称:海泰新光 青岛海泰新光科技股份有限公司 2024 年第四次临时股东大会会议须知 为了维护青岛海泰新光科技股份有限公司全体股东的合法权益,确保股东大 会的正常秩序和议事效率,保证大会的顺利进行,根据《中华人民共和国公司 法》、《中华人民共和国证券法》、中国证监会《上市公司股东大会规则》以及 《公司章程》、《青岛海泰新 ...
海泰新光:海泰新光2024年第三季度业绩说明会记录
2024-11-01 08:34
7、整机有受到医疗反腐的影响吗? A:国内医疗市场受反腐影响很大,今年上半年尤其明显,招标数 量很少,从下半年开始有所恢复。 8、以旧换新的推进情况? | 来访者类型 | 特定对象调研 分析师会议 策略会 | | | --- | --- | --- | | | 媒体采访  业绩说明会 | 新闻发布会 | | | 路演活动 公司来访 电话会议 |  其他 | | 来 访 人 员 姓 | 详见附件 | | | 名、身份证 | | | | 号及职务 | | | | 接待时间 | 10 月 28 日 预约接待地点 / | | | | 【130】人 接待人员 董事、总经理郑耀,独立 董事王鸣,副总经理、董 | | | 参会投资者 | | | | | 事会秘书、财务总监汪方 | | | | 华 | | | | 1、三季度内窥镜的发货情况?四季度和明年的情况会怎样? | | | | A:公司今年第三季度内窥镜发货数量是近几年来最少的一个季度, | | | | 主要是受大客户消库存的影响。目前大客户的库存已经降到了一个 | | | | 很低的水平,从第四季度和明年年初的发货需求来看,数量相比第 | | | | 三 ...
海泰新光:2024Q3业绩仍承压,拐点有望于2024Q4到来
Huaan Securities· 2024-11-01 07:03
Investment Rating - Buy rating maintained for Haitui New Light (688677) [1] Core Views - Performance pressure in 2024Q3, with a potential turning point expected in 2024Q4 [1] - Revenue for the first three quarters of 2024 was RMB 319 million, down 15.30% YoY, with net profit attributable to the parent company at RMB 97 million, down 17.60% YoY [1] - In 2024Q3, revenue was RMB 98 million, down 9.39% YoY, with net profit attributable to the parent company at RMB 27 million, down 7.00% YoY [1] - The decline in revenue is attributed to inventory reduction by a major US customer, but the rate of decline has narrowed compared to previous quarters [1] - Strong collaboration with the major US customer, with joint development of next-generation endoscope systems and plans to add anti-fogging features [1] - Overseas capacity expansion is progressing smoothly, with the US subsidiary in Nevada starting to receive orders and the Thai factory expected to achieve mass production by 2025 [1] Financial Projections - Revenue for 2024-2026 is projected to be RMB 437 million, RMB 542 million, and RMB 650 million, with growth rates of -7.1%, 24.1%, and 19.9% respectively [1] - Net profit attributable to the parent company for 2024-2026 is expected to be RMB 133 million, RMB 187 million, and RMB 226 million, with growth rates of -9.0%, 41.4%, and 20.5% respectively [1] - PE ratios for 2024-2026 are projected at 35x, 25x, and 20x [1] Financial Performance - Gross margin for 2023 was 63.7%, expected to increase to 65.3% in 2024, 66.0% in 2025, and 66.5% in 2026 [3] - ROE for 2023 was 11.3%, expected to be 9.3% in 2024, 11.6% in 2025, and 12.3% in 2026 [3] - EPS for 2024-2026 is projected to be RMB 1.10, RMB 1.55, and RMB 1.87 [3] Operational Highlights - The company's US subsidiary in Nevada passed customer certification in July 2024 and began receiving orders for endoscopes [1] - The 4mm hysteroscope developed for the US customer has entered mass production, with shipments starting in June 2024 [1] - The Thai factory obtained BUI and production licenses in 2024Q3, with plans to apply for customer approval in November and December 2024, aiming for mass production in 2025Q1 [1]
海泰新光:2024三季报点评:业绩短期承压,下游去库存逐步见底
Soochow Securities· 2024-10-31 00:30
Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's performance is under short-term pressure due to downstream inventory destocking, but the destocking process is nearing its end [2] - The company's Q3 revenue remains under pressure, with a single-quarter revenue of 98 million yuan (-9.39% YoY) and net profit of 27 million yuan (-7.00% YoY) [2] - The company is actively expanding overseas, with its Thailand subsidiary expected to achieve mass production next year, enhancing its competitiveness [2] - The company's main business is expected to recover steadily next year, supported by stable cooperation with a major US customer and the domestic equipment replacement policy [3] - The report adjusts the company's net profit forecasts for 2024-2026 to 140/204/250 million yuan, with corresponding PE valuations of 31/21/17 times [3] Financial Performance - The company's revenue for the first three quarters of 2024 was 319 million yuan (-15.30% YoY), with net profit of 97 million yuan (-17.60% YoY) [2] - The company's revenue for 2024 is expected to be 395.41 million yuan (-15.98% YoY), with net profit of 139.62 million yuan (-4.18% YoY) [1] - The company's revenue for 2025 is expected to be 523.29 million yuan (+32.34% YoY), with net profit of 203.63 million yuan (+45.85% YoY) [1] - The company's revenue for 2026 is expected to be 631.96 million yuan (+20.77% YoY), with net profit of 250.13 million yuan (+22.83% YoY) [1] Business Segments - The company's medical endoscope products and light source modules saw a decline in revenue due to downstream inventory destocking, while endoscope maintenance and complete equipment sales showed significant growth [2] - The company sold approximately 150 sets of complete equipment in the first three quarters of 2024, with full-year sales expected to grow steadily [2] Overseas Expansion - The company's Thailand factory has obtained BUI and production licenses, with production lines for new endoscope products and light source modules established [2] - The company plans to apply for customer approval in November and December, aiming for mass production in the first quarter of next year [2] Valuation and Metrics - The company's current PE ratio is 31.19 times, with expected PE ratios of 21.38 and 17.41 times for 2025 and 2026, respectively [1] - The company's current PB ratio is 3.40 times, with expected PB ratios of 3.14, 2.74, and 2.37 times for 2024, 2025, and 2026, respectively [10] - The company's ROE for 2024 is expected to be 10.08%, increasing to 12.82% and 13.61% in 2025 and 2026, respectively [10] Market Data - The company's closing price is 36.10 yuan, with a one-year low/high of 25.48/61.99 yuan [5] - The company's market capitalization is 4,354.17 million yuan, with a circulating A-share market capitalization of 4,354.17 million yuan [5] Financial Statements - The company's total assets are expected to increase from 1,395 million yuan in 2023 to 1,962 million yuan in 2026 [9] - The company's net cash flow from operating activities is expected to increase from 158 million yuan in 2023 to 331 million yuan in 2026 [10] - The company's capital expenditures are expected to be 92 million yuan in 2024, 92 million yuan in 2025, and 94 million yuan in 2026 [10]
海泰新光:大客户库存持续消化,整机业务加速成熟
ZHONGTAI SECURITIES· 2024-10-27 08:15
Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is experiencing a continuous inventory digestion from major clients, leading to an acceleration in the maturity of its complete machine business. Despite a decline in revenue and net profit in the first three quarters of 2024, the company is expected to see a gradual recovery in shipment volumes as client inventory levels decrease. The international business localization capabilities are improving significantly, which is anticipated to enhance the competitiveness of domestic operations [1][3]. Financial Performance Summary - **Revenue (in million CNY)**: - 2022: 477 - 2023: 471 - 2024E: 414 - 2025E: 517 - 2026E: 653 - **Year-over-Year Growth Rate**: - 2022: 54% - 2023: -1% - 2024E: -12% - 2025E: 25% - 2026E: 26% [1] - **Net Profit (in million CNY)**: - 2022: 183 - 2023: 146 - 2024E: 146 - 2025E: 178 - 2026E: 221 - **Year-over-Year Growth Rate**: - 2022: 55% - 2023: -20% - 2024E: 1% - 2025E: 21% - 2026E: 24% [1] - **Earnings Per Share (in CNY)**: - 2022: 2.10 - 2023: 1.20 - 2024E: 1.20 - 2025E: 1.46 - 2026E: 1.82 [1] Business Outlook - The company has reported a revenue of 3.19 billion CNY for the first three quarters of 2024, a year-over-year decline of 15.30%. The net profit for the same period is 0.97 billion CNY, down 17.60% year-over-year. The decline is attributed to the impact of major clients reducing inventory levels [1][3]. - The company is expected to see a recovery in shipment volumes as client inventory levels decrease, with a focus on expanding its international business and enhancing local delivery capabilities [1][3]. Cost and Profitability Analysis - The company has increased its marketing and R&D investments, leading to a relatively stable profitability profile. The sales expense ratio for the first three quarters of 2024 is reported at 4.91%, with management and financial expense ratios also showing slight increases [1][3]. - The gross profit margin for the first three quarters of 2024 is 65.74%, reflecting a year-over-year increase, while the net profit margin is reported at 30.78%, showing a slight decline [1][3].